No photo of Sunandana Chandra

View Scopus Profile

Sunandana Chandra

  • 655 Citations
20122022
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.

Training Experience

2011Residency, Case Western Reserve University Hospital
2014Fellowship, New York University Medical Center

Education/Academic qualification

MD, Michigan State University

… → 2008

MS, Michigan State University

… → 2003

Research interests

  • Cancer of Unknown Primary
  • Clinical Research
  • Drug Discovery
  • Melanoma
  • Skin Cancer

Fingerprint Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
CTLA-4 Antigen Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2022

Prot #R2810-ONC-1806: Cemiplimab Survivorship Epidemiology (CASE) Study

Chandra, S.

inVentiv Health Clinical, Regeneron Pharmaceuticals, Inc.

12/5/19 → 12/5/22

Project: Research project

Prot #HCRN MEL17-309/NU G18M02: Phase II Single-Arm Multi-Center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-Risk Ocular Melanoma

Chandra, S.

Hoosier Cancer Research Network, Inc., Bristol-Myers Squibb Company

10/22/19 → 10/22/22

Project: Research project

Prot #CA224083: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 T

Chandra, S.

Bristol-Myers Squibb Company

9/25/19 → 9/25/22

Project: Research project

Prot #GO40558: A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Melanoma

Chandra, S.

Covance Inc., Genentech, Inc.

9/11/19 → 9/11/22

Project: Research project

Prot #KRT-232-103: A Phase 2, Open-Label, Single-Arm Study of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy

Chandra, S.

Syneos Health, Inc., Kartos Therapeutics, Inc.

5/2/19 → 5/2/22

Project: Research project

Research Output 2012 2020

Sebaceous carcinoma: controversies and their evidence for clinical practice

Kibbi, N., Worley, B., Owen, J. L., Kelm, R. C., Bichakjian, C. K., Chandra, S., Demirci, H., Kim, J. Y. S., Nehal, K. S., Thomas, J. R., Samuelson, E. P. & Alam, M., Jan 1 2020, In : Archives of Dermatological Research. 312, 1, p. 25-31 7 p.

Research output: Contribution to journal › Review article

Carcinoma
Sentinel Lymph Node Biopsy
Neoplasms
Skin
DNA Mismatch Repair

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J. E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., Barker, K., Liang, Y., Warren, S., Beechem, J. M., Menzies, A. M., Tio, M., Long, G. V., Cohen, J. V., Guidon, A. C., O’Hare, M. & 13 others, Chandra, S., Chowdhary, A., Lebrun-Vignes, B., Goldinger, S. M., Rushing, E. J., Buchbinder, E. I., Mallal, S. A., Shi, C., Xu, Y., Moslehi, J. J., Sanders, M. E., Sosman, J. A. & Balko, J. M., Aug 1 2019, In : Nature Medicine. 25, 8, p. 1243-1250 8 p.

Research output: Contribution to journal › Letter

T-cells
Encephalitis
Human Herpesvirus 4
Chemical activation
T-Cell Antigen Receptor

Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

Research output: Contribution to journal › Letter

1 Citation (Scopus)

Clinical characterization of colitis arising from anti-PD-1 based therapy

Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 others, Gibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

Research output: Contribution to journal › Article

Colitis
Steroids
Therapeutics
Prednisone
Melanoma
2 Citations (Scopus)

Evidence-Based Clinical Practice Guidelines for Microcystic Adnexal Carcinoma: Informed by a Systematic Review

Worley, B., Owen, J. L., Barker, C. A., Behshad, R., Bichakjian, C. K., Bolotin, D., Bordeaux, J. S., Bradshaw, S., Cartee, T. V., Chandra, S., Cho, N., Choi, J., Council, M. L., Eisen, D. B., Golda, N., Huang, C. C., Ibrahim, S. F., Jiang, S. I. B., Kim, J., Lacutoure, M. & 26 others, Lawrence, N., Lee, E. H., Leitenberger, J. J., Maher, I. A., Mann, M., Minkis, K., Mittal, B., Nehal, K. S., Neuhaus, I., Ozog, D. M., Petersen, B., Samie, F., Shin, T. M., Sobanko, J. F., Somani, A. K., Stebbins, W. G., Thomas, J. R., Thomas, V., Tse, D., Waldman, A., Xu, Y. G., Yu, S. S., Zeitouni, N. C., Ramsay, T., Poon, E. & Alam, M., Sep 2019, In : JAMA dermatology. 155, 9, p. 1059-1068 10 p.

Research output: Contribution to journal › Review article

Evidence-Based Practice
Practice Guidelines
Carcinoma
Sweat Glands
Skin